Abstract:Abstract OBJECTIVES End-stage congenital heart disease (CHD) in children with heterotaxy syndrome might necessitate a heart transplant (HTx). An HTx in heterotaxy patients can be associated with several technical (e.g. redo, systemic/pulmonary-venous/situs anomalies, pulmonary artery reconstruction) and extra-cardiac (e.g. ciliary dyskinesia, infections, gastrointestinal) challenges. Our goal was to determine if heterotaxy syndrome is associated with increased early or late transplant risks. METHODS The United Network for Organ Sharing transplant database was merged with the Paediatric Health Information System administrative database to identify children with heterotaxy who received an HTx. Characteristics and outcomes were compared between children with heterotaxy and contemporaneous non-heterotaxy congenital and non-congenital cardiomyopathy control groups. RESULTS After we merged the databases, we divided our cohort of 1122 patients into 3 groups: the heterotaxy (n = 143), group the non-heterotaxy congenital (n = 428) group and the cardiomyopathy (n = 551) group. There were differences in the characteristics between the 3 groups, with the heterotaxy group being comparable to the non-heterotaxy congenital group. The waiting list duration was longer for the heterotaxy than for the non-heterotaxy congenital and cardiomyopathy groups (91 vs 63 vs 56 days, P < 0.001). Early post-transplant complications were similar for all groups except for operative mortality, which was 1% for the cardiomyopathy and 4% for the heterotaxy and non-heterotaxy congenital groups (P < 0.001). The post-transplant hospital stay was shorter for the cardiomyopathy (57 days) compared to the non-heterotaxy congenital (99 days) and heterotaxy (89 days) groups (P < 0.001). Whereas rejection prior to discharge was comparable between the heterotaxy and the CHD groups, it was higher at 1 year for the heterotaxy (22%) than for the non-heterotaxy congenital (19%) and cardiomyopathy (13%) groups (P < 0.001). Survival at 5 years was superior for the cardiomyopathy (87%) compared to the heterotaxy (69%) and non-heterotaxy congenital groups (78%) (P < 0.001). For the heterotaxy group, no risk factors affecting survival were identified on multivariable analysis. CONCLUSIONS Regardless of the complexity, an HTx in selected children with heterotaxy is associated with good mid-term outcomes. Despite early results that are comparable to those of other patients with CHD, the increasing rejection rate at 1 year and the relatively accelerated attrition at mid-term warrant further follow-up. Due to database limitations in defining morphologic and surgical details, further work is warranted to delineate anatomical and surgical variables that could affect survival.

Heart transplantation for pediatric patients with malignant arrhythmias: Indications and Outcomes

Primary Cardiac Tumors in Children: a Center's Experience.

Arrhythmias in children undergoing orthotopic heart transplantation

Outcomes of heart transplantation in children with previously palliated hypoplastic left heart syndrome

Cardiac transplantation in pediatric patients: fifteen-year experience of a single center

Influence of cardiac diagnosis on outcomes of pediatric heart-lung transplantation

Trends and outcomes of heart transplantation in adults with congenital heart disease

They Deserve to Live: Impact of the Berlin Heart EXCOR on Small Children's Heart Transplant Waitlist in Low-Resource Settings

Outcomes of heart transplants in children with heterotaxy syndrome

Mechanical circulatory support early after pediatric heart transplantation-an analysis from the Pediatric Heart Transplant Society

Paediatric heart transplantation: life-saving but not yet a cure

Young patient presenting with cardiogenic shock and refractory ventricular tachycardia: a case of unsuspected arrhythmogenic cardiomyopathy leading to urgent heart transplantation

Changes in waiting time, need for mechanical circulatory support and outcomes in paediatric heart transplant recipients

Heart Transplantation for Adults With Congenital Heart Disease Can Be Performed at Adult or Pediatric Hospitals With Comparable Outcomes

Impact of medication non-adherence on survival after pediatric heart transplantation in the U.S.A

Pediatric heart allocation and transplantation in Eurotransplant

Waitlist Outcomes for Pediatric Heart Transplantation in the Current Era: An Analysis of the Pediatric Heart Transplant Society Database

Pathology of explanted pediatric hearts: An 11‐year study. Population characteristics and implications for outcomes

Is heart transplantation a real option in patients with Duchenne syndrome? Inferences from a case report

Surgical Treatment of Primary Cardiac Tumor Associated with Malignant Arrhythmias

Survival after Cardiac Transplantation in Patients with Hypertrophic Cardiomyopathy